Expression and Significance of TRAILR in Human Glioblastoma
-
摘要: 目的: 研究TRAIL受体(TRAIL receptor,TRAILR)在胶质母细胞瘤中的表达,探讨其临床意义. 方法: 联合采用免疫组化和原位杂交方法检测胶质母细胞瘤及正常脑组织中TRAILR的表达. 结果: 22例胶质母细胞瘤均大量表达死亡受体(Death receptor,DR)DR4和DR5,9例(40.9%)表达诱骗受体(Decoy receptor,DcR)DcR1,5例(22.7%)表达DcR2,而20例正常脑组织普遍表达DcR,8例(40.0%)表达DR4,6例(30.0%)表达DR5.胶质母细胞瘤组织中DR的高表达以及DcR的低表达不同于正常脑组织中DR的低表达及DcR的高表达,两者间差异有显著性(P<0.01).原位杂交显示,22例胶质母细胞瘤组织分别有19例(864%)DcR1和17例(77.3%)DcR2在mRNA水平呈阳性表达,DcR在转录水平的表达明显高于翻译水平(P<0.01). 结论: 胶质母细胞瘤中普遍存在DR的高表达和DcR的低表达,DcR在胶质母细胞瘤中限制性表达的调控位于转录后水平.这可能为胶质母细胞瘤的凋亡诱导治疗提供新的靶点和新的策略.Abstract: Objective :To investigate the expression and significance of TRAILR in human glioblastoma. Methods :The expression of TRAILR was determined by immunohistochemistry and in situ hybridization jointly in 22 samples of glioblastoma and 20 samples of normal brain tissue. Results :With low DcR expression in partial glioblastoma cells and low DR expression in partial normal brain cells, DR was expressed highly in all glioblastoma samples while DcR in most normal brain tissue. High DR expression and low DcR expression in glioblastoma tissue differed from low DR expression and high DcR expression in normal brain tissue (P<0.01). We also found there was significant difference between the DcR expression in mRNA level and that in protein level(P<0.01). Conclusions :High DR expressign and low DcR expression are prevalent in glioblastoma tissue. The control of DcR expression exists in protein level. This may supply the new target point and strategy for the apoptosis-induced therapy of glioblastoma.
-
Keywords:
- Glioblastoma /
- TRAIL /
- Apoptosis
-
-
[1] Wiley SR,Schooley K,Smolak PJ. Identification and characterization of a new member of the TNF family that induces apoptosis[J].Immunity,1995,(06):673-682. [2] Pitti RM,Marsters SA,Ruppert S. Induction of apoptosis by Apo-2 ligand,a new member of the tumor necrosis factor cytokine family[J].Journal of Biological Chemistry,1996,(22):12687-12690. [3] Ashkenazi A,Dixit VM. Death receptors:signaling and modulation[J].Science,1998,(5381):1305-1308. [4] Pan G,ORourke K,Chinnaiyan AM. The receptor for the cytotoxic ligand TRAIL[J].Science,1997,(5309):111-113. [5] Pan G,Ni J,Wei YF. An antagonist decoy receptor and a death domain-containing receptor for TRAIL[J].Science,1997,(5327):815-818. [6] Emery JG,Mcdonnell P,Burke MB. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[J].Journal of Biological Chemistry,1998,(23):14363-14367. [7] 王忠城. 神经外科学[M].武汉:湖北科学技术出版社,1998.428-429. [8] 曹长军,袁先厚,侯炜. TRAIL受体在脑胶质瘤中的表达[J].中华医学杂志,2002,(01):38-39. [9] Arizonon Y,Yoshikawa H,Naganuma H. A mechanism of resistance to TRAIL/APO2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents[J].British Journal of Cancer,2003,(02):298-306. [10] Le Blanc HN,Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors[J].Cell Death,2003,(01):66-75.
计量
- 文章访问数: 3
- HTML全文浏览量: 0
- PDF下载量: 1
下载:
